In response to the accumulating evidence linking Lp(a) to CVD, several professional societies have recently issued or updated their clinical guidance regarding Lp(a) with a trend among recent guideline publications towards advocating for universal Lp(a) screening among all adults (2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS), 2021 Canadian Cardiovascular Society (CCS) dyslipidemia guidelines, and 2022 EAS Lp(a) consensus statement) [27••, 32, 33] (Table 1). The gene discussed is LPA; the disease is metabolic syndrome.